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A total of 138503 women in the Women’s Health Initiative in the United States were followed (for an average of 7.7 years) through
12 September 2005 to examine obesity, especially central obesity in relation to pancreatic cancer (n¼251). Women in the highest
quintile of waist-to-hip ratio had 70% (95% confidence interval 10–160%) excess risk of pancreatic cancer compared with women in
the lowest quintile.
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Pancreatic cancer ranks as the fourth leading cause of cancer death
in the United States (Ekbom and Hunter, 2007). Besides tobacco
smoking and chronic pancreatitis (Lowenfels et al, 1999), little is
known of its aetiology, but recently, increasing evidence has
suggested that obesity is a risk factor (Berrington de Gonzalez
et al, 2003; Larsson et al, 2007). However, in most studies, the
association seems to be weaker in women – who tend to gain
weight more peripherally – than in men, suggesting that central
adiposity may be a stronger risk factor for pancreatic cancer than
body mass index (BMI). Few studies have investigated this aspect
and the findings are inconsistent (Larsson et al, 2005; Sinner et al,
2005; Ansary-Moghaddam et al, 2006; Berrington de Gonzalez
et al, 2006).
We have used the large prospective Women’s Health Initiative
(WHI) study, with measured anthropometric factors, including hip
and waist circumference, to examine the relationship between BMI,
central adiposity, and pancreatic cancer risk.
MATERIALS AND METHODS
Women’s Health Initiative
The WHI, an ongoing, ethnically and geographically diverse,
multi-centre clinical trial (CT) and observational study (OS), was
designed to address some of the major causes of morbidity and
mortality in postmenopausal women. Briefly, a total of 161808
women aged 50–79 years were recruited at 40 clinical centres
throughout the United States from 1 September 1993 through 1998.
The WHI includes three overlapping CT components (hormone
trial, dietary modification trial, and calcium/vitamin D supple-
mentation trial) and an OS. All participants in WHI gave informed
consent and were followed prospectively. Details of the scientific
rationale, eligibility requirements and baseline characteristics of
the participants in the WHI have been published elsewhere (Hays
et al, 2003; Jackson et al, 2003; Langer et al, 2003; Ritenbaugh et al,
2003; Stefanick et al, 2003).
The following participants were excluded from the original
cohort of 161808:14849 with a history of cancer (except non-
melanoma skin cancer) at baseline, 668 with no follow-up, 7491
with missing values of main exposures and confounders (including
weight, height, waist circumference, hip circumference, smoking,
and diabetes), and 297 (0.18%) with waist-to-hip ratio (WHR)
values of beyond 4 s.d. (WHRo0.4 or WHR41.2), leaving 138503
women for analysis.
All exposures in our analyses were collected at baseline for all
participants. During the baseline clinical visit, trained and certified
staff performed anthropometric measurements, including height,
weight, hip and waist circumferences, and blood pressure. Body
mass index was calculated as weight in kilograms divided by the
square of height in metres. Waist circumference at the natural
waist or narrowest part of the torso and hip circumference at the
maximal circumference were measured to the nearest 0.1cm. WHR
was computed as the ratio of these two measurements. Weight
changes during the participant’s adult lives were obtained by self-
report questionnaire, categorized as weight stayed stable (within
10lb), steady gain in weight, lost weight as an adult and kept it off,
and weight has gone up and down again by more than 10lb.
Information on demographic characteristics, medical history,
and personal habits (lifestyle) were obtained by interview or by
self-report using standardized questionnaires including age at
enrolment (o55, 55–59, 60–64, 65–69, 70–74, 75–), smoking
status (never, past, current) with information on how many years
since quitting for past smokers and how many cigarettes smoked
per day for ever smokers, physical activity and history of
hypertension and diabetes while not pregnant.
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examinations to ensure timely ascertainment of updated medical
histories. All women in the CT were expected to attend annual
clinical visits, with intermediate 6-month mail, phone or clinical
contacts. The OS participants were contacted annually by mailed
self-administered questionnaires. The completion rate of OS
annual questionnaires was 93–96%. In this analysis, all partici-
pants were followed up until 12 September 2005. Initial reports of
cancer were ascertained by self-administered questionnaires, and
all self-reports of pancreatic cancer were confirmed by review of
medical records, including pathology reports (if a biopsy or
resection was done).
Statistical analyses
The hazard ratio (HR) for pancreatic cancer was estimated using
the Cox proportional hazards model. Different study cohorts
(participation in OS or CTs, and different treatment assignments
for all three CTs) were treated as strata in the model. In the
multivariable models, we adjusted for age, smoking status (never,
former smoking (quitted timeX30 years, 20–29, 10–19, and o10
years), and current smoking (o4, 5–14, 15–24, 25 and more
cigarettes per day)). As diabetes could be in the causal pathway
between obesity and risk, we performed analyses (both adjusted
and unadjusted) for this factor.
We treated anthropometric measures as categorical (in quin-
tiles) variables in the regression models, except BMI which was
categorized (o22, 22–o25, 25–o30, 30–o35, and X35kg m
 2).
Tests for trend were performed by creating a continuous variable
from the medians of the categories. In addition, to eliminate
undiagnosed cases that might have experienced weight loss before
completing the baseline questionnaires, we also performed
analyses that excluded the first 2 years of follow-up. The
proportional assumption was satisfied for all exposure variables
of interest and potential confounding variables based on graphs of
scaled Schoenfeld residuals (Hess, 1995).
RESULTS
As of 12 September 2005 with an average 7.7 years of follow-up,
251 incident cases of pancreatic cancer had been identified.
Characteristics at baseline of selected variables by quintile of WHR
are shown in Table 1. Compared with women with lower WHR,
those with higher WHR were older, non-white, and less educated.
Women with higher WHR were also more likely to be past or
current smokers and tended to smoke more cigarettes per day and
to have quit more recently, to have higher total energy intake, be
less physically active, and have higher prevalence of diabetes and
hypertension. WHR was positively associated with weight, BMI,
waist and hip circumference.
Among the tested anthropometric variables, only WHR was
significantly associated with the risk of pancreatic cancer. After
adjusting for potential confounders, women in the highest quintile
of WHR had 70% (95% CI 10–160%) excess risk compared with
women in the lowest quintile of WHR. When WHR was analyzed
as a continuous variable, risk increased by 27% (95% CI 7–50%)
per 0.1 increase. No association was observed between pancreatic
cancer risk and other anthropometric variables, including height,
BMI, hip circumference, waist circumference, and weight changes
during adult life (Table 2).
Finally, we repeated all the above analyses with the exclusion of
the first 2 years of follow-up; findings remained broadly similar to
Table 1 Baseline characteristics of participants in relation to WHR (quintiles) among 138503 postmenopausal women
a
WHR (quintile, range)
Variable 1 (0.40–0.75) 2 (0.75–0.79) 3 (0.79–0.82) 4 (0.82–0.87) 5 (0.87–1.20)
Total number of women 27707 27694 27736 27651 27715
Age at baseline (mean, years) 61.4 62.7 63.3 63.7 64.2
White, non-Hispanic-ethnicity (%) 86.9 84.3 82.0 79.6 79.6
College graduate or above education (%) 48.1 43.1 38.3 34.9 31.3
Ever smoking (%)
Past 37.6 39.2 40.1 41.1 42.8
Quit o20 years(%) 41.4 44.3 46.5 51.3 54.5
Current 5.0 6.7 7.2 7.8 8.9
X15 cigarettesday
 1 (%) 40.4 43.3 48.5 49.3 53.9
Dietary intake (mean)
Total energy intake (kcalday
 1) 1580 1611 1638 1679 1727
Fruit and vegetable(median servings per day) 4.3 4.2 4.1 3.9 3.9
Physical activity (METs per week) 15.2 13.8 12.3 11.0 9.7
Diabetes mellitus (%) 1.4 2.3 4.0 6.9 14.2
Hypertension (%) 19.4 26.0 32.5 39.5 48.8
Weight (kg, mean) 65.5 69.1 72.8 77.1 81.8
Height (cm, Mean) 162.4 162.0 161.7 161.5 161.5
BMI (kgm
 2, mean) 24.9 26.3 27.8 29.5 31.3
Waist circumference (mean, cm) 73.8 80.2 85.6 91.8 100.8
Hip circumference (mean, cm) 103.3 104.5 106.5 108.7 109.5
WHR (mean) 0.71 0.77 0.80 0.85 0.92
Type of weight change
Steady gain in weight 23.6 30.3 34.4 38.0 39.6
Lost weight and kept it off 4.3 3.0 2.2 1.8 1.4
Weight upon and down (more than 10lb) 27.6 31.0 34.3 37.4 41.1
BMI¼body mass index; MET¼metabolic equivalent tasks; WHR¼waist-to-hip ratio.
aAll comparisons of cohort characteristics by waist-to-hip levels are significantly different,
with Po0.0001 based on w
2 test for categorical variables and analysis of variance (ANOVA) test for continuous variables.
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comparing women in the highest to the lowest of WHR.
DISCUSSION
In this large prospective study, we observed that central obesity
measured by high WHR, rather than general obesity measured by
high BMI, was associated with an increased risk of developing
pancreatic cancer among postmenopausal women.
Our result is consistent with most earlier studies for central
adiposity and pancreatic cancer (Larsson et al, 2005; Patel et al,
2005; Ansary-Moghaddam et al, 2006; Berrington de Gonzalez
et al, 2006), although not all (Sinner et al, 2005). In particular, the
large prospective European prospective investigation into cancer
and nutrition (EPIC) study (Berrington de Gonzalez et al, 2006)
also observed significant increased risk associated with higher
WHR (HR¼1.24 (1.04–1.48) per 0.1 increase of WHR), but not
with BMI. In fact, there was a weak or no association among
women in all but 4 (Michaud et al, 2001; Calle et al, 2003; Pan et al,
2004; Patel et al, 2005) of the 16 studies published since 2000 on
the association between the risk of pancreatic cancer and BMI that
included women (Coughlin et al, 2000; Gapstur et al, 2000; Nilsen
and Vatten, 2000; Hanley et al, 2001; Michaud et al, 2001; Wolk
et al, 2001; Calle et al, 2003; Pan et al, 2004; Eberle et al, 2005;
Fryzek et al, 2005; Larsson et al, 2005; Patel et al, 2005; Rapp et al,
2005; Sinner et al, 2005; Lin et al, 2007; Nothlings et al, 2007).
The link between obesity and pancreatic cancer – similar to the
plausible mechanism between diabetes and pancreatic cancer –
may arise as a result of elevated fasting and postprandial glucose
concentration, hyperinsulinemia, or both (Everhart and Wright,
1995; Gapstur et al, 2000; Batty et al, 2004; Jee et al, 2005). Many
experimental studies (Pour and Stepan, 1984; Pour et al, 1990;
Schneider et al, 2001; Wang et al, 2003; Hennig et al, 2004) and
Table 2 Age-adjusted and multivariate-adjusted HR of pancreatic cancer by baseline measures of adiposity among 138503 postmenopausal women
Variable No. of cases
Age-adjusted HR
(95% CI)
Multi-adjusted HR
(95% CI)
a
Multi-adjusted HR
(95% CI)
b
Height (cm)
1 (100.0–156.4, 153.6) 63 Reference Reference Reference
2 (156.5–160.1, 158.5) 54 1.0 (0.7–1.4) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
3 (160.2–163.4, 161.9) 48 0.9 (0.6–1.3) 0.8 (0.6–1.2) 0.8 (0.6–1.2)
4 (163.5–167.0, 165.1) 43 0.9 (0.6–1.2) 0.8 (0.5–1.1) 0.8 (0.5–1.1)
5 (167.1–212.0, 170.0) 43 0.9 (0.6–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
P (trend) 0.4 0.3 0.3
BMI (kg m
 2)
o22.0 25 0.8 (0.5–1.2) 0.8 (0.5–1.2) 0.8 (0.5–1.2)
22.0–24.9 62 Reference Reference Reference
25.0–29.9 84 0.9 (0.6–1.2) 0.9 (0.6–1.2) 0.9 (0.6–1.2)
30.0–34.9 56 1.2 (0.8–1.7) 1.1 (0.8–1.6) 1.1 (0.7–1.5)
35.0– 24 0.9 (0.6–1.4) 0.9 (0.5–1.4) 0.8 (0.5–1.3)
P (trend) 0.4 0.5 0.9
Hip (cm) quintile (range, median)
1 (40.0–96.9, 93.0) 52 Reference Reference Reference
2 (97.0–101.9, 99.0) 58 1.2 (0.8–1.7) 1.2 (0.8–1.8) 1.2 (0.8–1.8)
3 (102.0–107.1, 104.3) 50 1.0 (0.6–1.4) 1.0 (0.6–1.4) 0.9 (0.6–1.4)
4 (107.1–115.0, 111.0) 42 0.9 (0.6–1.3) 0.9 (0.6–1.3) 0.8 (0.6–1.3)
5 (115.1–200.0, 122.5) 49 1.1 (0.7–1.6) 1.1 (0.7–1.6) 1.0 (0.7–1.5)
P (trend) 0.7 0.6 0.4
Waist (cm) quintile (range, median)
1 (35.0–74.5, 70.5) 41 Reference Reference Reference
2 (74.6–81.0, 78.0) 50 1.2 (0.8–1.7) 1.1 (0.7–1.7) 1.1 (0.7–1.7)
3 (81.1–88.0, 85.0) 46 1.1 (0.7–1.6) 1.0 (0.7–1.6) 1.0 (0.7–1.6)
4 (88.1–97.4, 92.4) 63 1.5 (1.0–2.2) 1.4 (1.0–2.1) 1.4 (0.9–2.0)
5 (97.5–194.2, 105.0) 51 1.3 (0.9–1.9) 1.2 (0.8–1.8) 1.1 (0.7–1.6)
P (trend) 0.1 0.2 0.6
Waist as continuous (per 10cm) 251 1.10 (1.00–1.20) 1.08 (0.98–1.18) 1.05 (0.95–1.15)
WHR quintile (range, median)
1 (0.40–0.75, 0.72) 34 Reference Reference Reference
2 (0.75–0.79, 0.77) 47 1.3 (0.8–2.0) 1.3 (0.8–1.9) 1.2 (0.8–1.9)
3 (0.79–0.82, 0.80) 44 1.2 (0.7–1.8) 1.1 (0.7–1.7) 1.1 (0.7–1.7)
4 (0.82–0.87, 0.84) 48 1.2 (0.8–1.9) 1.2 (0.7–1.8) 1.1 (0.7–1.7)
5 (0.87–1.20, 0.91) 78 2.0 (1.4–3.0) 1.8 (1.2–2.8) 1.7 (1.1–2.6)
P (trend) 0.0003 0.002 0.01
WHR as continuous (per 0.1) 251 1.38 (1.17–1.63) 1.32 (1.12–1.56) 1.27 (1.07–1.50)
Type of weight change
Stable weight 85 Reference Reference Reference
Steady gain in weight 77 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.9 (0.6–1.2)
Lost weight and kept it off 5 0.7 (0.3–1.6) 0.6 (0.3–1.6) 0.6 (0.3–1.5)
Weight up and down (more than 10lb) 83 1.0 (0.7–1.3) 0.9 (0.7–1.3) 0.9 (0.7–1.2)
CI¼confidence interval; HR¼hazard ratio; WHR¼waist-to-hip ratio.
aAdjusted variables included age, different treatment assignments in clinical trials, and smoking status
(never, former smoking (quitted timeX30years, 20-o30, 10-o20, o10 years), and current smoking (o4, 5–14, 15–24, 25 and more cigarettes per day)).
bFurther adjusted for
diabetes history at baseline.
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2000; Huxley et al, 2005; Stolzenberg-Solomon et al, 2005) support
the biological plausibility of higher insulin concentrations and
insulin resistance in promoting pancreatic cancer development. If
the induced insulin resistance is the underlying mechanism
through which obesity increases the risk, then it is not surprising
that we observed a stronger association with WHR abdominal
adiposity than with BMI among postmenopausal women, because
central adiposity is more strongly associated with glucose
intolerance and increased insulin levels (Carey et al, 1997; Van
Pelt et al, 2001; Sierra-Johnson et al, 2004; Tanko et al, 2004). In
addition, the body fat distribution changes significantly following
menopause, with a shift from preferential storage in gluteal/
femoral regions to abdominal depots. Thus, our finding further
suggests that the central adiposity is a better predictor of disease
risk than BMI in postmenopausal women (Van Pelt et al, 2001).
Strengths of our study include the prospective design, the large
size of the cohort, the reasonably large number of cases, the high
prevalence of obesity, including central adiposity, the detailed
information on potential confounders, and the precise measure-
ment of anthropometric factors. Measurement rather than
self-reporting is particularly important for waist and hip
circumferences, which are likely to be reported less accurately
than height and weight. There is a possibility of misclassification
among the cases, given the difficulty in diagnosis of this disease.
However, this misclassification is likely to be non-differential with
respect to anthropometric measurements, which may make our
results conservative. A second possibility was weight loss because
of undiagnosed disease, but results did not change after excluding
the first 2 years of follow-up. It is unlikely that pancreatic cancer
advanced enough to cause weight loss would remain undiagnosed
for more than 2 years.
In conclusion, our large prospective study shows that increased
central adiposity was associated with an increased risk of
developing pancreatic cancer among postmenopausal women.
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